DDInter397 DDInter1651
Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
Human secretin is a gastrointestinal peptide hormone that regulates secretions in the stomach, pancreas, and liver. The hormone is produced from the enterochromaffin cells in the duodenum in response to the duodenal content with the pH less than 4.5 . The main action of secretin is to stimulate the pancreas to secrete pancreatic juice for pH regulation in the small intestines. Secretin is also responsible in body fluid homeostasis and bile production. Although it is a gastrointestinal hormone, secretin is also considered as a neuropeptide hormone since it is also expressed in the central nervous system . Purified synthetic human secretin, also referred to as RG1068, is available as an intravenous injection under the market name ChiRhoStim ® in the U.S.. It contains an amino acid sequence identical to the naturally occurring hormone consisting of 27 amino acids [FDA Label] that supports α-helical formation . The carboxyl-terminal amino acid, valine, is amidated. Synthetic human secretin displays equivalent biological activity and properties as naturally-occurring secretin . It is indicated for the stimulation of the pancreatic and gastric secretions to aid in the diagnosis of pancreatic exocrine dysfunction and the diagnosis of gastrinoma, and facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP).
Clidinium {u} (Compound) resembles {v} (Compound) Diphenylpyraline
Clidinium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mepenzolate
Clidinium {u} (Compound) binds {v} (Gene) CHRM3
Clidinium {u} (Compound) is included by {v} (Pharmacologic Class) Cholinergic Antagonists
Clidinium {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bendroflumethiazide
Clidinium {u} may cause a minor interaction that can limit clinical effects when taken with {v} Hydrochlorothiazide
Clidinium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Hyoscyamine
Clidinium {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Clidinium {u} may lead to a major life threatening interaction when taken with {v} Zonisamide
Clidinium {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Darifenacin
Clidinium (Compound) resembles Diphenylpyraline (Compound)
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Clidinium (Compound) binds CHRM3 (Gene)
Clidinium (Compound) is included by Cholinergic Antagonists (Pharmacologic Class)
Clidinium may cause a minor interaction that can limit clinical effects when taken with Bendroflumethiazide
Clidinium may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine
Clidinium may lead to a major life threatening interaction when taken with Potassium chloride
Clidinium may lead to a major life threatening interaction when taken with Zonisamide
Clidinium (Compound) resembles Darifenacin (Compound) and Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Darifenacin